Charles River Laboratories Inte (CRL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $3.02
- Estimate
- $2.74
- Surprise
- +10.3%
- Revenue (period 2026-06-27)
- $1.00B
- Score today
- 4.4/10
Revenue source: xbrl.
How the report landed
Charles River Laboratories Inte (CRL) beat the $2.74 estimate with adjusted EPS of $3.02 — a large 10.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRL Sell at 4.4/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +10.3% surprise compares with a +5.4% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: DSA segment (59.8%)
- Target reached (-5.7% upside)
- Quality below floor (2.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $299.02
- Price target
- $326.63
- Stop
- $278.09
- Upside to target
- +9.2%
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
CRL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $14.27B
- P/E (fwd)
- 23.4
- 52-week range
- $146.20–$333.30
- Off 52-week high
- 10.3%
- RSI (14)
- 65
- Volume vs avg
- 0.73×
- Score today
- 4.4/10